戈利木单抗。
Golimumab.
机构信息
Genetics Graduate Program, Department of Anatomy and Cell Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA.
出版信息
MAbs. 2009 Sep-Oct;1(5):422-31. doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15.
Abstract
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.
摘要
戈利木单抗是一种人抗 TNFalpha IgG1kappa 单克隆抗体，于 2009 年 4 月在美国和加拿大获批用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎，目前正在欧盟进行这些适应证的监管审查。该产品由 Centocor 和 Janssen Pharmaceutical KK（强生的子公司）与先灵葆雅和武田制药合作开发。戈利木单抗在市场上面临众多蛋白治疗竞争对手，但作为首个患者可自行给药、每月一次给药的抗 TNFalpha 药物，它可能是患者的一个有吸引力的选择。
相似文献
1
Golimumab.戈利木单抗。
MAbs. 2009 Sep-Oct;1(5):422-31. doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15.
2
Golimumab, a fully human monoclonal antibody against TNFalpha.戈利木单抗，一种完全人源化的抗肿瘤坏死因子α单克隆抗体。
Curr Opin Mol Ther. 2008 Aug;10(4):393-406.
3
Golimumab (simponi) for inflammatory arthritis.戈利木单抗（欣普尼）用于治疗炎性关节炎。
Med Lett Drugs Ther. 2009 Jul 13;51(1316):55-6.
4
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.戈利木单抗：用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎。
BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005.
5
Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.戈利木单抗：一种新型肿瘤坏死因子-α抑制剂的疗效和耐受性评价。
Clin Ther. 2010 Sep;32(10):1681-703. doi: 10.1016/j.clinthera.2010.09.003.
6
Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.戈利木单抗治疗类风湿关节炎的临床疗效及不良反应
Isr Med Assoc J. 2012 Jun;14(6):390-4.
7
Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗：一种用于治疗类风湿性关节炎、银屑病关节炎和强直性脊柱炎的新型抗肿瘤坏死因子-α人单克隆抗体。
Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434.
8
Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗：一种新型抗 TNF-α 药物，用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎。
Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49.
9
Golimumab, the newest TNF-α blocker, comes of age.最新的肿瘤坏死因子-α阻滞剂戈利木单抗已走向成熟。
Clin Exp Rheumatol. 2015 Jul-Aug;33(4):570-7. Epub 2015 Jan 20.
10
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.戈利木单抗的免疫原性及其在类风湿关节炎、银屑病关节炎和强直性脊柱炎患者中的临床相关性。
Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.
引用本文的文献
1
Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.红皮病型银屑病的最新进展：通过创新的严重程度评估方法提出管理算法建议。
Psoriasis (Auckl). 2025 Jul 19;15:301-320. doi: 10.2147/PTT.S532062. eCollection 2025.
2
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.阿巴西普、戈利木单抗和托珠单抗作为当前治疗中具有不同作用机制的选定生物原研改善病情抗风湿药。
J Clin Med. 2025 Mar 19;14(6):2107. doi: 10.3390/jcm14062107.
3
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss.一组市售抗体在生理pH值和温度下的体外稳定性研究，作为筛选生物候选分子体内天冬酰胺脱酰胺化和活性丧失潜在风险的指南。
Pharm Res. 2025 Feb;42(2):353-363. doi: 10.1007/s11095-025-03825-3. Epub 2025 Feb 20.
4
Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.用于炎症性指甲疾病的生物制剂和小分子药物：一篇叙述性综述。
Indian Dermatol Online J. 2024 Dec 26;16(1):50-58. doi: 10.4103/idoj.idoj_445_24. eCollection 2025 Jan-Feb.
5
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.用于治疗抗肾小球基底膜病的免疫生物制剂。
Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014.
6
Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.长效戈利木单抗的持久性：类风湿关节炎、银屑病关节炎和强直性脊柱炎关键性 III 期临床试验汇总的 5 年治疗保留数据。
Clin Rheumatol. 2023 Dec;42(12):3397-3405. doi: 10.1007/s10067-023-06760-z. Epub 2023 Sep 26.
7
Biologics and Biosimilars in Psoriasis.银屑病中的生物制剂和生物类似药
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
8
Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases.自身免疫性风湿性疾病生物治疗中的抗药物抗体
J Clin Med. 2023 May 4;12(9):3271. doi: 10.3390/jcm12093271.
9
Therapeutic Strategies Targeting Pancreatic Islet β-Cell Proliferation, Regeneration, and Replacement.靶向胰腺胰岛 β 细胞增殖、再生和替代的治疗策略。
Endocrinology. 2022 Nov 14;164(1). doi: 10.1210/endocr/bqac193.
10
Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.咽上磨蚀疗法（EAT）降低慢性咽炎中主要促炎细胞因子 IL-6 的 mRNA 表达。
Int J Mol Sci. 2022 Aug 16;23(16):9205. doi: 10.3390/ijms23169205.
本文引用的文献
1
E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.尽管接受了甲氨蝶呤治疗，但E选择素、白细胞介素18、血清淀粉样蛋白A和基质金属蛋白酶9与活动性类风湿关节炎患者接受戈利木单抗加甲氨蝶呤治疗的临床反应相关。
J Rheumatol. 2009 Jul;36(7):1371-9. doi: 10.3899/jrheum.080755. Epub 2009 Jun 1.
2
Tocilizumab: a review of its use in the management of rheumatoid arthritis.托珠单抗：类风湿关节炎治疗应用综述
Drugs. 2009;69(5):609-32. doi: 10.2165/00003495-200969050-00007.
3
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.戈利木单抗，一种新型人肿瘤坏死因子α抗体，每四周皮下注射一次用于治疗银屑病关节炎：一项随机、安慰剂对照研究的24周疗效和安全性结果。
Arthritis Rheum. 2009 Apr;60(4):976-86. doi: 10.1002/art.24403.
4
Prospective new biological therapies for rheumatoid arthritis.类风湿关节炎的新型生物治疗药物。
Autoimmun Rev. 2009 Dec;9(2):102-7. doi: 10.1016/j.autrev.2009.03.010. Epub 2009 Mar 26.
5
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.一项关于肿瘤坏死因子-α阻断剂治疗重度持续性哮喘的随机、双盲、安慰剂对照研究。
Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8.
6
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.戈利木单抗，一种通过每月皮下注射给药的抗肿瘤坏死因子α人源抗体，用于尽管接受了甲氨蝶呤治疗但仍处于活动期的类风湿性关节炎：GO-FORWARD研究。
Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9.
7
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.戈利木单抗治疗强直性脊柱炎患者的疗效与安全性：一项随机、双盲、安慰剂对照的III期试验结果
Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.
8
Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-alpha in Cynomolgus Macaques.综述治疗性单克隆抗体对食蟹猴白细胞介素 6 和肿瘤坏死因子-α的临床前安全性和免疫调节作用。
J Immunotoxicol. 2005 Jul 1;1(3):131-9. doi: 10.1080/15476910490894904.
9
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.在已接受甲氨蝶呤治疗的活动性类风湿关节炎患者中使用戈利木单抗：一项随机、双盲、安慰剂对照、剂量范围研究。
Arthritis Rheum. 2008 Apr;58(4):964-75. doi: 10.1002/art.23383.
10
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.美国关节炎及其他风湿性疾病患病率的估计。第一部分。
Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177.
Zotero 插件